Document Detail


Antihypertensive treatment in patients with class 3 obesity.
MedLine Citation:
PMID:  23148200     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Even though patients with class 3 obesity (body mass index ≥ 40 kg/m(2)) are prone to arterial hypertension and respond less to antihypertensive drugs, they are not considered in hypertension treatment guidelines and data from prospective clinical trials are lacking.
METHODS: In a post hoc analysis of a clinical trial, we compared patients with class 3 obesity with patients with class 1/2 obesity.
RESULTS AND CONCLUSIONS: Blood pressure control in class 3 obesity was less likely to be achieved with hydrochlorothiazide monotherapy. While addition of amlodipine, irbesartan, or aliskiren to hydrochlorothiazide improved the blood pressure response, amlodipine was less effective and induced peripheral edema in 19% of patients with class 3 obesity.
Authors:
Jens Jordan; Sam W Boye; Stephanie Le Breton; Deborah L Keefe; Stefan Engeli; Margaret Forney Prescott
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Therapeutic advances in endocrinology and metabolism     Volume:  3     ISSN:  2042-0196     ISO Abbreviation:  Ther Adv Endocrinol Metab     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-11-13     Completed Date:  2012-11-19     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  101532143     Medline TA:  Ther Adv Endocrinol Metab     Country:  United States    
Other Details:
Languages:  eng     Pagination:  93-8     Citation Subset:  -    
Affiliation:
Institute of Clinical Pharmacology, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Rationale and design of PATRO Adults, a multicentre, noninterventional study of the long-term effica...
Next Document:  Efficacy and safety of insulin lispro protamine suspension as basal supplementation in patients with...